Anixa Biosciences Stock Performance
| ANIX Stock | USD 3.30 0.01 0.30% |
Anixa Biosciences has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Anixa Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Anixa Biosciences is expected to be smaller as well. Anixa Biosciences right now shows a risk of 4.27%. Please confirm Anixa Biosciences sortino ratio, as well as the relationship between the semi variance and rate of daily change , to decide if Anixa Biosciences will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Anixa Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady forward indicators, Anixa Biosciences may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return (0.30) | Five Day Return (1.49) | Year To Date Return (16.03) | Ten Year Return (12.00) | All Time Return (81.58) |
Last Split Factor 1:25 | Last Split Date 2015-06-26 |
1 | Acquisition by Titterton Lewis H Jr of 21646 shares of Anixa Biosciences at 3.06 subject to Rule 16b-3 | 09/12/2024 |
2 | Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine | 09/24/2024 |
3 | Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development | 10/07/2024 |
4 | Disposition of 16000 shares by Titterton Lewis H Jr of Anixa Biosciences at 2.575 subject to Rule 16b-3 | 10/22/2024 |
5 | Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the th Society for Immunotherapy of Cancer Annu... | 10/28/2024 |
6 | Acquisition by Catelani Michael of 500000 shares of Anixa Biosciences subject to Rule 16b-3 | 10/30/2024 |
7 | Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the th Society for Immunotherapy of Canc... | 11/08/2024 |
8 | Anixa stock rises as Bitcoin added to treasury - Seeking Alpha | 11/22/2024 |
| Begin Period Cash Flow | 12.4 M |
Anixa |
Anixa Biosciences Relative Risk vs. Return Landscape
If you would invest 323.00 in Anixa Biosciences on September 1, 2024 and sell it today you would earn a total of 7.00 from holding Anixa Biosciences or generate 2.17% return on investment over 90 days. Anixa Biosciences is currently generating 0.1192% in daily expected returns and assumes 4.2684% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Anixa, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Anixa Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anixa Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Anixa Biosciences, and traders can use it to determine the average amount a Anixa Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0279
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ANIX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Anixa Biosciences is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Anixa Biosciences by adding it to a well-diversified portfolio.
Anixa Biosciences Fundamentals Growth
Anixa Stock prices reflect investors' perceptions of the future prospects and financial health of Anixa Biosciences, and Anixa Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Anixa Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 86.01 M | ||||
| Shares Outstanding | 32.18 M | ||||
| Price To Earning | (51.83) X | ||||
| Price To Book | 4.89 X | ||||
| Price To Sales | 481.54 X | ||||
| Revenue | 210 K | ||||
| Gross Profit | 127.5 K | ||||
| EBITDA | (10.96 M) | ||||
| Net Income | (9.93 M) | ||||
| Cash And Equivalents | 31.66 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 175 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.01 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (6.21 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Market Capitalization | 106.19 M | ||||
| Total Asset | 25.52 M | ||||
| Retained Earnings | (228.2 M) | ||||
| Working Capital | 23.33 M | ||||
| Current Asset | 10.38 M | ||||
| Current Liabilities | 1.36 M | ||||
About Anixa Biosciences Performance
Evaluating Anixa Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Anixa Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Anixa Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (459.73) | (482.71) | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.54) | (0.57) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.46) | (0.49) |
Things to note about Anixa Biosciences performance evaluation
Checking the ongoing alerts about Anixa Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Anixa Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Anixa Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 210 K. Net Loss for the year was (9.93 M) with profit before overhead, payroll, taxes, and interest of 127.5 K. | |
| Anixa Biosciences currently holds about 31.66 M in cash with (6.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| Anixa Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Anixa stock rises as Bitcoin added to treasury - Seeking Alpha |
- Analyzing Anixa Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Anixa Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Anixa Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Anixa Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Anixa Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Anixa Biosciences' stock. These opinions can provide insight into Anixa Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.